Antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion

References

• AndréoliLGaudoneixMBeauveriePde BeaurepaireROff-label prescriptions in public psychiatric hospital practiceTherapie2013686347359 French24246118
   PubMed Web of Science ®Google Scholar
• AssionHJJungckCOff-label prescribing in a German psychiatric hospitalPharmacopsychiatry2007401303617327958
   PubMed Web of Science ®Google Scholar
• HawCStubbsJOff-label psychotropic prescribing for young persons in medium securityJ Psychopharmacol201024101491149819423609
   PubMed Web of Science ®Google Scholar
• MarkTLFor what diagnoses are psychotropic medications being prescribed? A nationally representative survey of physiciansCNS Drugs201024431932620297856
   PubMed Web of Science ®Google Scholar
• ThompsonWQuayTARojas-FernandezCFarrellBBjerreLMAtypical antipsychotics for insomnia: a systematic reviewSleep Med201622131727544830
   PubMed Web of Science ®Google Scholar
• WalittBKlosePUçeylerNPhillipsTHäuserWAntipsychotics for fibromyalgia in adultsCochrane Database Syst Rev20166CD011804
   Google Scholar
• NieoullonADopamine and the regulation of cognition and attentionProg Neurobiol2002671538312126656
   PubMed Web of Science ®Google Scholar
• HoriHNoguchiHHashimotoRAntipsychotic medication and cognitive function in schizophreniaSchizophr Res2006861–313814616793238
   PubMed Web of Science ®Google Scholar
• KnowlesEEDavidASReichenbergAProcessing speed deficits in schizophrenia: reexamining the evidenceAm J Psychiatry2010167782883520439390
   PubMed Web of Science ®Google Scholar
• TorniainenMSuvisaariJPartonenTCognitive impairments in schizophrenia and schizoaffective disorder: relationship with clinical characteristicsJ Nerv Ment Dis2012200431632222456585
   PubMed Web of Science ®Google Scholar
• HusaAPRannikkoIMoilanenJLifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia: an observational 9-year follow-up studySchizophr Res20141581–313414125034761
   PubMed Web of Science ®Google Scholar
• HusaAPMoilanenJMurrayGKLifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohortPsychiatry Res201724713013827888683
   PubMed Web of Science ®Google Scholar
• MisharaALGoldbergTEA meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed bookBiol Psychiatry200455101013102215121486
   PubMed Web of Science ®Google Scholar
• HarveyPDKeefeRSStudies of cognitive change in patients with schizophrenia following novel antipsychotic treatmentAm J Psychiatry2001158217618411156796
   PubMed Web of Science ®Google Scholar
• ZhangJPGallegoJARobinsonDGMalhotraAKKaneJMCorrellCUEfficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysisInt J Neuropsychopharmacol20131661205121823199972
   PubMed Web of Science ®Google Scholar
• CummingPImaging DopamineCambridgeCambridge University Press2009
   Google Scholar
• AminFDavidsonMDavisKLHomovanillic acid measurement in clinical research: a review of methodologySchizophr Bull19921811231481553492
   PubMed Web of Science ®Google Scholar
• BacopoulosNGHattoxSERothRH3,4-Dihydroxyphenylacetic acid and homovanillic acid in rat plasma: possible indicators of central dopaminergic activityEur J Pharmacol1979563225236477719
   PubMed Web of Science ®Google Scholar
• KendlerKSHsiehJYDavisKLStudies of plasma homovanillic acid as an index of brain dopamine functionPsychopharmacol Bull19821841521557156280
   PubMedGoogle Scholar
• LambertGWEisenhoferGJenningsGLEslerMDRegional homovanillic acid production in humansLife Sci199353163758515683
   PubMed Web of Science ®Google Scholar
• MaasJWContrerasSAMillerALStudies of catecholamine metabolism in schizophrenia/psychosis – INeuropsychopharmacology199382971098471132
   PubMed Web of Science ®Google Scholar
• ArrueADavilaRZumarragaMGABA and homovanillic acid in the plasma of schizophrenic and bipolar I patientsNeurochem Res201035224725319701707
   PubMed Web of Science ®Google Scholar
• DuncanEWolkinAAngristBPlasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenicsBiol Psychiatry19933485235288274579
   PubMed Web of Science ®Google Scholar
• JavaidJISharmaRPJanicakPGDavisJMPlasma HVA in psychiatric patients: longitudinal studiesPsychopharmacol Bull19902633613652274637
   PubMedGoogle Scholar
• KakiharaSYoshimuraRShinkaiKPrediction of response to risperidone treatment with respect to plasma concentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6Int Clin Psychopharmacol2005202717815729081
   PubMed Web of Science ®Google Scholar
• KelleyMEYaoJKvan KammenDPPlasma catecholamine metabolites as markers for psychosis and antipsychotic response in schizophreniaNeuropsychopharmacology199920660361110327429
   PubMed Web of Science ®Google Scholar
• KoreenARLiebermanJAlvirJPlasma homovanillic acid levels in first-episode schizophrenia: psychopathology and treatment responseArch Gen Psychiatry19945121321387905259
   PubMed Web of Science ®Google Scholar
• MazureCMNelsonJCJatlowPIBowersMBPlasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosisBiol Psychiatry19913054754821932395
   PubMed Web of Science ®Google Scholar
• PetrieECFaustmanWOMosesJALombrozoLCsernanskyJGCorrelates of rapid neuroleptic response in male patients with schizophreniaPsychiatry Res19903321711772243894
   PubMed Web of Science ®Google Scholar
• SumiyoshiTKurachiMKurokawaKPlasma homovanillic acid in the prodromal phase of schizophreniaBiol Psychiatry200047542843310704954
   PubMed Web of Science ®Google Scholar
• SodaEMiuraIHoshinoHImpacts of age on plasma monoamine metabolite concentrations in a large cohort of healthy individualsPsychiatry Res20142201–263964525200191
   PubMed Web of Science ®Google Scholar
• KumakuraYVernalekenIBuchholzHGAge-dependent decline of steady state dopamine storage capacity of human brain: an FDOPA PET studyNeurobiol Aging2017313447463
   Web of Science ®Google Scholar
• LeeRCoccaroEFPlasma homovanillic acid correlates inversely with history of childhood trauma in personality disordered and healthy control adultsJ Neural Transm2010117111327133420953642
   PubMed Web of Science ®Google Scholar
• RoyASelf-rated childhood emotional neglect and CSF monoamine indices in abstinent cocaine-abusing adults: possible implications for suicidal behaviorPsychiatry Res20021121697512379452
   PubMed Web of Science ®Google Scholar
• SumiyoshiTYotsutsujiTKurachiMItohHKurokawaKSaitohOEffect of mental stress on plasma homovanillic acid in healthy human subjectsNeuropsychopharmacology199819170739608578
   PubMed Web of Science ®Google Scholar
• FitzgeraldPDinanTGProlactin and dopamine: what is the connection? A review articleJ Psychopharmacol2008222 Suppl121918477617
   PubMedGoogle Scholar
• Ben-JonathanNHnaskoRDopamine as a prolactin (PRL) inhibitorEndocr Rev200122672476311739329
   PubMed Web of Science ®Google Scholar
• MolitchMEMedication-induced hyperprolactinemiaMayo Clin Proc20058081050105716092584
   PubMed Web of Science ®Google Scholar
• MeltzerHYFangVSThe effect of neuroleptics on serum prolactin in schizophrenic patientsArch Gen Psychiatry19763332792861259521
   PubMed Web of Science ®Google Scholar
• GründerGWetzelHSchlösserRNeuroendocrine response to antipsychotics: effects of drug type and genderBiol Psychiatry199945189979894580
   PubMed Web of Science ®Google Scholar
• DeutschländerAla FougèreCBoetzelKOccupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson’s disease patientsNeuroimage Clin201612414627408789
   PubMed Web of Science ®Google Scholar
• FrankMJO’ReillyRCA mechanistic account of striatal dopamine function in human cognition: psychopharmacological studies with cabergoline and haloperidolBehav Neurosci2006120349751716768602
   PubMed Web of Science ®Google Scholar
• FirstMBSpitzerRLGibbonMWilliamsJBStructured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version Nonpatient edNew YorkBiometrics Research2002
   Google Scholar
• DaviesMAShefflerDJRothBLAripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacologyCNS Drug Rev200410431733615592581
   PubMedGoogle Scholar
• RothBLShefflerDJKroezeWKMagic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophreniaNat Rev Drug Discov20043435335915060530
   PubMed Web of Science ®Google Scholar
• BerlantJLNeuroleptics and reserpine in refractory psychosesJ Clin Psychopharmacol1986631801842872238
   PubMed Web of Science ®Google Scholar
• HenryJPBottonDSagneCBiochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granulesJ Exp Biol19941962512627823026
   PubMed Web of Science ®Google Scholar
• KannariKTanakaHMaedaTTomiyamaMSudaTMatsunagaMReserpine pretreatment prevents increases in extracellular striatal dopamine following L-dopa administration in rats with nigrostriatal denervationJ Neurochem200074126326910617128
   PubMed Web of Science ®Google Scholar
• BeckATWardCHMendelsonMMockJErbaughJAn inventory for measuring depressionArch Gen Psychiatry1961456157113688369
   PubMed Web of Science ®Google Scholar
• HamiltonMA rating scale for depressionJ Neurol Neurosurg Psychiatry196023566214399272
   PubMed Web of Science ®Google Scholar
• KaySRFiszbeinAOplerLAThe positive and negative syndrome scale (PANSS) for schizophreniaSchizophr Bull19871322612763616518
   PubMed Web of Science ®Google Scholar
• LindenmayerJPBernstein-HymanRGrochowskiSBarkNPsychopathology of schizophrenia: initial validation of a 5-factor modelPsychopathology199528122317871117
   PubMed Web of Science ®Google Scholar
• Marsh-RichardDMHatzisESMathiasCWVendittiNDoughertyDMAdaptive visual analog scales (AVAS): a modifiable software program for the creation, administration, and scoring of visual analog scalesBehav Res Methods20094119910619182128
   PubMed Web of Science ®Google Scholar
• VeselinovićTSchornHVernalekenIBSchifflKKlompMGründerGImpact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretionJ Clin Psychopharmacol201131221422021346608
   PubMed Web of Science ®Google Scholar
• MinegishiAIshizakiTDetermination of free 3-methoxy-4-hydroxyphenylglycol with several other monoamine metabolites in plasma by high-performance liquid chromatography with amperometric detectionJ Chromatogr1984311151576520169
   PubMed Web of Science ®Google Scholar
• DavidsonDFSimultaneous assay for urinary 4-hydroxy-3-methoxy-mandelic acid, 5-hydroxyindoleacetic acid and homovanillic acid by isocratic HPLC with electrochemical detectionAnn Clin Biochem198926Pt 21371432471433
   PubMed Web of Science ®Google Scholar
• VeselinovićTSchornHVernalekenIEffects of antipsychotic treatment on psychopathology and motor symptoms: a placebo-controlled study in healthy volunteersPsychopharmacology (Berl)2011218473374821643673
   PubMed Web of Science ®Google Scholar
• VeselinovićTSchornHVernalekenIBEffects of antipsychotic treatment on cognition in healthy subjectsJ Psychopharmacol201327437438523118022
   PubMed Web of Science ®Google Scholar
• SreemantulaSBoiniKMNammiSReserpine methonitrate, a novel quaternary analogue of reserpine augments urinary excretion of VMA and 5-HIAA without affecting HVA in ratsBMC Pharmacol200443015546495
   PubMedGoogle Scholar
• CarlssonALindqvistMEffect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brainActa Pharmacol Toxicol (Copenh)19632014014414060771
   PubMedGoogle Scholar
• KaroumFChrapustaSJEganMF3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool modelJ Neurochem19946339729797914228
   PubMed Web of Science ®Google Scholar
• O’KeeffeRSharmanDFVogtMEffect of drugs used in psychoses on cerebral dopamine metabolismBr J Pharmacol19703822873044984801
   PubMed Web of Science ®Google Scholar
• MagliozziJRDoranARGietzenDWOlsonAMMaclinELTuasonVBEffects of single dose haloperidol administration on plasma homovanillic acid levels in normal subjectsPsychiatry Res19934721411498341767
   PubMed Web of Science ®Google Scholar
• DavidsonMDavisKLA comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controlsArch Gen Psychiatry19884565615633377642
   PubMed Web of Science ®Google Scholar
• HoriHYoshimuraRYamadaYEffects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patientsInt Clin Psychopharmacol2007221212717159456
   PubMed Web of Science ®Google Scholar
• DavilaRGonzalezMAZumarragaMPlasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophreniaBiol Psychiatry19953842672698547450
   PubMed Web of Science ®Google Scholar
• PickarDLabarcaRLinnoilaMNeuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patientsScience198422546659549576474162
   PubMed Web of Science ®Google Scholar
• PickarDLabarcaRDoranARLongitudinal measurement of plasma homovanillic acid levels in schizophrenic patients: correlation with psychosis and response to neuroleptic treatmentArch Gen Psychiatry19864376696763718170
   PubMed Web of Science ®Google Scholar
• SharmaRJavaidJIJanicakPFaullKComatyJDavisJMPlasma and CSF HVA before and after pharmacological treatmentPsychiatry Res1989281971042740469
   PubMed Web of Science ®Google Scholar
• YoshimuraRNakamuraJUedaNTeraoTEffect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels, and clinical improvementInt Clin Psychopharmacol200015317518010870876
   PubMed Web of Science ®Google Scholar
• YoshimuraRUedaNShinkaiKNakamuraJPlasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophreniaInt Clin Psychopharmacol200318210711112598823
   PubMed Web of Science ®Google Scholar
• GraceAABunneyBSMooreHToddCLDopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugsTrends Neurosci20172013137
   Web of Science ®Google Scholar
• DavilaRManeroEZumarragaMAndiaISchweitzerJWFriedhoffAJPlasma homovanillic acid as a predictor of response to neurolepticsArch Gen Psychiatry19884565645673377643
   PubMed Web of Science ®Google Scholar
• BowersMBJSwigarMEJatlowPIGoicoecheaNPlasma catecholamine metabolites and early response to haloperidolJ Clin Psychiatry19844562482516725216
   PubMed Web of Science ®Google Scholar
• ChangWHChenTYLeeCFHungJCHuWHYehEKPlasma homovanillic acid levels and subtyping of schizophreniaPsychiatry Res19882332392443387499
   PubMed Web of Science ®Google Scholar
• DavidsonMKahnRSKnottPEffects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrationsArch Gen Psychiatry199148109109131929760
   PubMed Web of Science ®Google Scholar
• van PuttenTMarderSRAravagiriMChabertNMintzJPlasma homovanillic acid as a predictor of response to fluphenazine treatmentPsychopharmacol Bull198925189912772121
   PubMedGoogle Scholar
• VernalekenIKumakuraYBuchholzHGBaseline [18F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: a positron emission tomography study in healthy subjectsNeuroimage20084031222123118262797
   PubMed Web of Science ®Google Scholar
• de BartolomeisATomasettiCIasevoliFUpdate on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonismCNS Drugs201529977379926346901
   PubMed Web of Science ®Google Scholar
• JordanSKoprivicaVDunnRTottoriKKikuchiTAltarCAIn vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic functionEur J Pharmacol20044831455314709325
   PubMed Web of Science ®Google Scholar
• KikuchiTTottoriKUwahodoY7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activityJ Pharmacol Exp Ther199527413293367616416
   PubMed Web of Science ®Google Scholar
• KoenerBFocantMCBosierBMaloteauxJMHermansEIncreasing the density of the D2L receptor and manipulating the receptor environment are required to evidence the partial agonist properties of aripiprazoleProg Neuropsychopharmacol Biol Psychiatry2012361607021871520
   PubMed Web of Science ®Google Scholar
• MaGFRaivioNSabríaJOrtizJAgonist and antagonist effects of aripiprazole on D2-like receptors controlling rat brain dopamine synthesis depend on the dopaminergic toneInt J Neuropsychopharmacol2014184pyu04625522390
   PubMed Web of Science ®Google Scholar
• FriedhoffAJA dopamine-dependent restitutive system for the maintenance of mental normalcyAnn N Y Acad Sci198646347522872848
   PubMed Web of Science ®Google Scholar
• KaminskiRPowchickPWarnePAGoldsteinMMcQueeneyRTDavidsonMMeasurement of plasma homovanillic acid concentrations in schizophrenic patientsProg Neuropsychopharmacol Biol Psychiatry19901432712872193315
   PubMed Web of Science ®Google Scholar
• SuzukiEKanbaSNibuyaMLongitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patientsBiol Psychiatry199436106546617880934
   PubMed Web of Science ®Google Scholar
• RibeyreJMLesieurPVaroquauxODollfusSPaysMPetitMA comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophreniaBiol Psychiatry19943642302367986887
   PubMed Web of Science ®Google Scholar
• ZhangZJPeetMRamchandCNShahSReynoldsGPPlasma homovanillic acid in untreated schizophrenia: relationship with symptomatology and sexJ Psychiatr Res2001351232811287053
   PubMed Web of Science ®Google Scholar
• BeugerMvan KammenDPKelleyMEYaoJDopamine turnover in schizophrenia before and after haloperidol withdrawal: CSF, plasma, and urine studiesNeuropsychopharmacology199615175868797194
   PubMed Web of Science ®Google Scholar
• Ramirez-BermudezJRuiz-ChowAPerez-NeriICerebrospinal fluid homovanillic acid is correlated to psychotic features in neurological patients with deliriumGen Hosp Psychiatry200830433734318585537
   PubMed Web of Science ®Google Scholar
• van der CammenTJTiemeierHEngelhartMJFekkesDAbnormal neurotransmitter metabolite levels in Alzheimer patients with a deliriumInt J Geriatr Psychiatry200621983884316955437
   PubMed Web of Science ®Google Scholar
• FervahaGTakeuchiHLeeJAntipsychotics and amotivationNeuropsychopharmacology20154061539154825567425
   PubMed Web of Science ®Google Scholar
• NaberDKarowALambertMSubjective well-being under the neuroleptic treatment and its relevance for complianceActa Psychiatr Scand Suppl20054272934
   Google Scholar
• NussPTessierCAntipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulprideCurr Med Res Opin201026478780120121655
   PubMed Web of Science ®Google Scholar
• Schennach-WolffRSeemüllerFObermeierMResponse and remission of subjective well-being in patients suffering from schizophrenia spectrum disordersEur Psychiatry201126528429220435447
   PubMed Web of Science ®Google Scholar
• de HaanLvan BruggenMLavalayeJBooijJDingemansPMLinszenDSubjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind studyAm J Psychiatry2003160230330912562577
   PubMed Web of Science ®Google Scholar
• LatasterJvan OsJde HaanLEmotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling studyJ Clin Psychiatry201172101397140421208588
   PubMed Web of Science ®Google Scholar
• MizrahiRRusjanPAgidOAdverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophreniaAm J Psychiatry2007164463063717403977
   PubMed Web of Science ®Google Scholar
• MizrahiRMamoDRusjanPGraffAHouleSKapurSThe relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychoticsInt J Neuropsychopharmacol200912571572119366489
   PubMed Web of Science ®Google Scholar
• CastanhoTCMoreiraPSPortugal-NunesCThe role of sex and sex-related hormones in cognition, mood and well-being in older men and womenBiol Psychol201410315816625196100
   PubMed Web of Science ®Google Scholar
• HenryJFSherwinBBHormones and cognitive functioning during late pregnancy and postpartum: a longitudinal studyBehav Neurosci20121261738521928875
   PubMed Web of Science ®Google Scholar
• SlopienRSlopienAWarenik-SzymankiewiczASerum prolactin concentration and severity of depression symptoms in climacteric womenClin Exp Obstet Gynecol201542674975126753478
   PubMed Web of Science ®Google Scholar
• MontalvoIGutierrez-ZotesACreusMIncreased prolactin levels are associated with impaired processing speed in subjects with early psychosisPLoS One201492e8942824586772
   PubMed Web of Science ®Google Scholar
• LeeBJLeeSJKimMKEffect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidoneClin Psychopharmacol Neurosci2013112606624023549
   PubMed Web of Science ®Google Scholar
• GianfrancescoFDPandinaGMahmoudRWuJWangRHPotential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based studyAnn Gen Psychiatry20098519210771
   PubMedGoogle Scholar
• PeuskensJPaniLDetrauxJde HertMThe effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive reviewCNS Drugs201428542145324677189
   PubMed Web of Science ®Google Scholar
• HaddadPMWieckAAntipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and managementDrugs200464202291231415456328
   PubMed Web of Science ®Google Scholar
• HoltRIMedical causes and consequences of hyperprolactinaemia: a context for psychiatristsJ Psychopharmacol2008222 Suppl283718477618
   PubMedGoogle Scholar
• NagaokaSIwamotoNAraiHFirst-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatmentBiol Psychiatry19974188578649099412
   PubMed Web of Science ®Google Scholar
• UmeneWYoshimuraRHoriHBlood levels of catecholamine metabolites and brain-derived neurotrophic factor in a case of Sydenham’s choreaWorld J Biol Psychiatry200910324825117965987
   PubMed Web of Science ®Google Scholar
• SteinbergJLGarverDLMoellerFGRaeseJDOrsulakPJSerum homovanillic acid levels in schizophrenic patients and normal control subjectsPsychiatry Res1993482931068416025
   PubMed Web of Science ®Google Scholar
• LehrlSTriebigGFischerBMultiple choice vocabulary test MWT as a valid and short test to estimate premorbid intelligenceActa neurologica Scandinavica19959153353457639062
   PubMed Web of Science ®Google Scholar
• GuptaRNWheltonCDetermination of plasma homovanillic acid by liquid chromatography with electrochemical detectionJ Chromatogr19925821–22362411491047
   PubMed Web of Science ®Google Scholar